Literature DB >> 30778865

Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.

Hui Shao1, Shuang Yang1, Vivian Fonseca2, Charles Stoecker1, Lizheng Shi3.   

Abstract

OBJECTIVE: Health utility decrements associated with diabetes mellitus complications are essential for calculating quality-adjusted life-years (QALYs) in patients for use in economic evaluation of diabetes interventions. Previous studies mostly focused on assessing the impact of complications on health utility at event year based on cross-sectional data. This study aimed to separately estimate health utility decrements associated with current and previous diabetes complications. RESEARCH DESIGN AND METHODS: The Health Utilities Index Mark 3 (HUI-3) was used to measure heath utility in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (N = 8713). Five macrovascular complications (myocardial infarction [MI], congestive heart failure [CHF], stroke, angina, and revascularization surgery [RS]) and three microvascular complications (nephropathy [renal failure], retinopathy [severe vision loss], and neuropathy [severe pressure sensation loss]) were included in a set of alternative modelling approaches including the ordinary least squares (OLS) model, fixed effects model, and random effects model to estimate the complication-related health utility decrements.
RESULTS: All macrovascular complications were associated with decrements of HUI-3 scores: MI (event year: - 0.042, successive years: - 0.011), CHF (event year: - 0.089, successive years: - 0.041), stroke (event year: - 0.204, successive years: - 0.101), angina (event year: - 0.010, successive years: - 0.032), and revascularization (event year: - 0.038, successive years: - 0.016) (all p < 0.05). For microvascular complications, severe vision loss (- 0.057), and severe pressure sensation loss (- 0.066) were significantly associated with decrements of HUI-3 scores (both p < 0.05). Hypoglycemia (both severe and symptomatic) was found to be associated with a 0.036 decrement of health utility at event year, and a 0.033 decrement of health utility at successive years. Results from an OLS model are preferred for supporting a microsimulation model while a fixed effects model is preferred to describe direct health impacts from complications.
CONCLUSIONS: Macrovascular and microvascular complications caused QALY decrements in patients with type 2 diabetes. While only part of the total impaired QALY is experienced during the event year, further QALY decrements for successive years were quite substantial.

Entities:  

Mesh:

Year:  2019        PMID: 30778865      PMCID: PMC7220804          DOI: 10.1007/s40273-019-00775-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

Review 1.  Health outcomes in economic evaluation: the QALY and utilities.

Authors:  Sarah J Whitehead; Shehzad Ali
Journal:  Br Med Bull       Date:  2010-10-29       Impact factor: 4.291

2.  Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index.

Authors:  Nan Luo; Jeffrey A Johnson; James W Shaw; David Feeny; Stephen Joel Coons
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

3.  The use of QALYs in clinical and patient decision-making: issues and prospects.

Authors:  Paul Kind; Jennifer Elston Lafata; Karl Matuszewski; Dennis Raisch
Journal:  Value Health       Date:  2009-03       Impact factor: 5.725

Review 4.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

5.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

6.  A utility maximization model for evaluation of health care programs.

Authors:  G W Torrance; W H Thomas; D L Sackett
Journal:  Health Serv Res       Date:  1972       Impact factor: 3.402

7.  Valuing health-related quality of life in diabetes.

Authors:  J Todd Coffey; Michael Brandle; Honghong Zhou; Deanna Marriott; Ray Burke; Bahman P Tabaei; Michael M Engelgau; Robert M Kaplan; William H Herman
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

8.  The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

Authors:  Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas
Journal:  Curr Med Res Opin       Date:  2004-08       Impact factor: 2.580

9.  Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Authors:  Philip Clarke; Alastair Gray; Rury Holman
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583

10.  Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

Authors:  Paul Glasziou; Jan Alexander; Elaine Beller; Philip Clarke
Journal:  Health Qual Life Outcomes       Date:  2007-04-27       Impact factor: 3.186

View more
  10 in total

Review 1.  Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.

Authors:  Marc Evans; Susanne Engberg; Mads Faurby; João Diogo Da Rocha Fernandes; Pollyanna Hudson; William Polonsky
Journal:  Diabetes Obes Metab       Date:  2021-12-09       Impact factor: 6.408

2.  Patient Health Utility Equations for a Type 2 Diabetes Model.

Authors:  Simon J Neuwahl; Ping Zhang; Haiying Chen; Hui Shao; Michael Laxy; Andrea M Anderson; Timothy E Craven; Thomas J Hoerger
Journal:  Diabetes Care       Date:  2020-12-04       Impact factor: 17.152

3.  Cdc42 Promotes ADSC-Derived IPC Induction, Proliferation, And Insulin Secretion Via Wnt/β-Catenin Signaling.

Authors:  Xing-Hua Xiao; Qi-Yuan Huang; Xian-Ling Qian; Jing Duan; Xue-Qiao Jiao; Long-Yuan Wu; Qing-Yun Huang; Jun Li; Xing-Ning Lai; Yu-Bo Shi; Li-Xia Xiong
Journal:  Diabetes Metab Syndr Obes       Date:  2019-11-13       Impact factor: 3.168

4.  Impaired glucose regulation, depressive symptoms, and health-related quality of life.

Authors:  Jannica S Selenius; Niko S Wasenius; Hannu Kautiainen; Minna Salonen; Mikaela von Bonsdorff; Johan G Eriksson
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10

5.  Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298-2306.

Authors:  Hui Shao; Lizheng Shi; Vivian Fonseca
Journal:  Diabetes Care       Date:  2020-02       Impact factor: 17.152

6.  The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study.

Authors:  Veronique Lambert-Obry; Jean-Philippe Lafrance; Michelle Savoie; Jean Lachaine
Journal:  JMIR Res Protoc       Date:  2022-03-28

7.  Decrements in health-related quality of life associated with adverse events in people with diabetes.

Authors:  Mi Jun Keng; Jose Leal; Louise Bowman; Jane Armitage; Borislava Mihaylova
Journal:  Diabetes Obes Metab       Date:  2021-12-20       Impact factor: 6.408

8.  Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.

Authors:  Odette S Reifsnider; Pratik Pimple; Sarah Brand; Evelien Bergrath Washington; Sharash Shetty; Nihar R Desai
Journal:  Diabetes Obes Metab       Date:  2022-01-11       Impact factor: 6.408

9.  Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.

Authors:  Emelie Andersson; Sofie Persson; Nino Hallén; Åsa Ericsson; Desirée Thielke; Peter Lindgren; Katarina Steen Carlsson; Johan Jendle
Journal:  Diabetologia       Date:  2020-09-24       Impact factor: 10.122

10.  Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases.

Authors:  Shihchen Kuo; Chun-Ting Yang; Hsuan-Ying Chen; Huang-Tz Ou
Journal:  J Diabetes Investig       Date:  2021-03-02       Impact factor: 4.232

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.